JIANGSU HENGRUI PHARMACEUT-H

Jiangsu Hengrui Pharmaceuticals sees a modest 0.67% rise amid market volatility—investors weigh its slow growth and potential for a rally.

Jiangsu Hengrui Pharma shows steady gains as earnings shift from loss to profit, driven by eye‑care and anti‑inflammatory sales, while market cap hits HK$367.6B.